CPMP-Note for guideline on Harmonization of requirements for influenza vaccine欧盟-流感疫苗标准指南.docxVIP

CPMP-Note for guideline on Harmonization of requirements for influenza vaccine欧盟-流感疫苗标准指南.docx

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit 12 March 1997 CPMP/BWP/214/96 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON HARMONISATION OF REQUIREMENTS FOR INFLUENZA VACCINES DISCUSSION IN THE BIOTECHNOLOGY WORKING PARTY (BWP) March 1996 TRANSMISSION TO THE CPMP July 1996 TRANSMISSION TO INTERESTED PARTIES July 1996 DEADLINE FOR COMMENTS January 1997 RE-SUBMISSION TOTHE BWP March 1997 RE-SUBMISSION TO THE CPMP March 1997 APPROVAL BYTHECPMP March 1997 DATE FOR COMING INTO OPERATION April 1997 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Switchboard: (+44-171) 418 8400 Fax: (+44-171)418 8551 E_Mail: mail@ /emea.html HARMONISATION OF REQUIREMENTS FOR INFLUENZA VACCINES (CPMP/BWP 口 14/96) Immediate package Outer packaging Package leaflet YEARLY CHOICE OF INFLUENZA VIRUS STRAINS FOR VACCINES WHO has three international influenza centres (at the National Institute for Medical Research in Mill Hill UK; and at the Centers for Disease Control in Atlanta, USA and at CSL Ltd, Parkville, Australia), which are assisted by national laboratories, designated by WHO. The national laboratories isolate viruses and then refer them to an international centre for detailed antigenic analysis. Reports are regularly sent to WHO in Geneva. Once a year, in mid-February, a meeting of WHO experts takes place in Geneva, leading to a recommendation on the influenza A and B virus variants which should be used for the production of vaccine for the coming season, but there remains very broad flexibility within this recommendation. The WHO recommendations are aimed worldwide and therefore need to be adapted to the epidemiological situation of the European Union (EU). The predominant influenza viruses are believed to be similar from one Member State of the EU to another, There is thus little scientific justification for different composition of vaccines throughout the EU. As from 1992, a meeting of EU experts will h

文档评论(0)

大明小刀 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档